The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting, celebrating its 25th year in 2022, is the premier event for professionals in gene and cell therapy.
Join us at booth 252 to learn more about our 16 years of experience in lentiviral vectors manufacturing !
Christine Duthoit, Cell engineering & Immunology Project Leader, will present the poster abstract on the use of LentiFlash® for clinical applications :
Extensive use of genome editing tools has revealed a great deal of unpredictability, both off- and on-target, in the outcome of their application. Discover how LentiFlash®, Flash Therapeutics' RNA delivery technology, provides efficient gene editing without cell toxicity, while preserving cell phenotype and stem cell differentiation capacity, and with a very low impact on genotoxicity, enhancing the potential of LentiFlash® particles for clinical gene therapy applications.
Régis Gayon, Vectorology & Cell engineering Manager, will present the poster abstract on efficient and safe delivery of multiple mRNA using non-integrative Bacteriophage-chimeric Retrovirus-like particles for in vivo applications.